Iovance Lifts FY2026 Revenue Guidance to $410-$420M, a $55M Midpoint Increase
IOVA has more than doubled off its 52-week low of $1.76.
Summary
Iovance raised FY2026 revenue guidance to $410-$420 million, a $55 million midpoint increase driven by strong Amtagvi and Proleukin demand, implying nearly 60% annual growth.
Key Events · Earnings and Guidance · IOVA
-
FY2026 Guidance Raised to $410-$420M
Full year 2026 revenue guidance increased by $55 million at the midpoint from the prior $350-$370 million range, implying nearly 60% annual growth.
-
Strong Commercial Momentum
Record Q2 2026 revenue of $99.3 million and sustained demand for Amtagvi and Proleukin drove the guidance raise.
-
ATC Network Expansion
Authorized treatment center network has grown to ~100 centers, with expansion to at least 110 expected by year-end 2026.
-
Q3 Results Timing
Third quarter 2026 financial results are expected to be reported in early November 2026.
Analysis · IOVA · Life Sciences
A $55 million midpoint increase lifts Iovance's full-year 2026 revenue guidance to $410-$420 million, implying nearly 60% annual growth. The raise follows record Q2 revenue of $99.3 million and reflects strong U.S. demand for Amtagvi and Proleukin. Management cited increasing patient demand and the current manufacturing schedule as providing strong visibility into Q3 and Q4 revenues. The company also disclosed that its ATC network has grown to ~100 centers, with expansion to at least 110 expected by year-end. This is a significant positive update that materially improves the revenue outlook and supports the commercial ramp of its TIL therapies.
How filings like this one have moved
In the 30 days to Oct 31, 2026, 40% of the 987 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.59%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IOVA was trading at $11.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5B. The 52-week trading range was $1.76 to $11.17. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.